Developing therapeutics for schizophrenia and other psychotic disorders

NeuroRx

Volumn 2, Issue 4, 2005, Pages 579-589

  Marek, Gerard ^a   Merchant, Kalpana ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Animal models; Genetic etiopathology; Investigational drugs; Neurodevelopmental etiology; Neuroimaging; Neurotransmission; Proof of concept clinical studies

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CATECHOL METHYLTRANSFERASE; CHLORPROMAZINE; CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; NEU DIFFERENTIATION FACTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; PERPHENAZINE; QUETIAPINE; REMOXIPRIDE; SEROTONIN 2A ANTAGONIST; SERTINDOLE; TALNETANT; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; UNINDEXED DRUG; ZIPRASIDONE;

AGRANULOCYTOSIS; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; DISEASE EXACERBATION; DRUG RESEARCH; EXTRAPYRAMIDAL SYMPTOM; GABAERGIC SYSTEM; HUMAN; NEGATIVE SYNDROME; NERVE CELL DIFFERENTIATION; NEUROBIOLOGY; NEUROIMAGING; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 25844440844     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.2.4.579     Document Type: Article

References (118)

1. Andreasen NC. A unitary model of schizophrenia. Bleuler's "Fragmented Phrene" as schizencephaly. Arch Gen Psychiatry 56:781-787, 1999.
2. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, B. Sheitman, Lindenmayer J-P, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159:1018-1028, 2002.
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553-564, 2003.
4. Harvey PD, Keefe RSE. Studies of cognitive change with treatment in schizophrenia. Am J Psychiatry 158:176-184, 2001.
5. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330, 1996.
6. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff." Schizophr Bull 26:119-136, 2000.
7. Geyer MA, Tamminga CA. Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects. Psychopharmacology 174:1-2, 2004.
8. Murray RM, Sham P, Van Os J, Zanelli J, Cannon M, McDonald C. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr Res 71:405-416, 2004.
9. Kety SS. Schizophrenic illness in the families of schizophrenic adoptees. Schizophr Bull 14:217-222, 1988.
10. Tsuang MT, Gilbertson MW, Faraone SV. The genetics of schziophrenia. Current knowledge and future directions. Schizophr Res 4:157-171, 1991.
11. Kendler KS. Overview: a current perspective on twin studies of schizophrenia. Am J Psychiatry 140:1413-1425, 1983.
12. Owen MJ, O'Donovan M, Gottesman II. Schizophrenia. Psychiatric genetics and genomics (McGuffin P, Owen MJ, Gottesman II, eds) pp 247-266. London: Oxford University Press, 2002.
13. Moldin SO. Report of the National Institute of Mental Health's Genetic Workgroup. Summary of Research. Biol Psychiatry 45:573-602, 1999.
14. Faraone SV, Tsuang MT. Quantitative models of the genetic transmission of schizophrenia. Psychol Bull 98:41-66, 1985
15. Risch N. Genetic linkage and complex diseases, with special reference to psychiatric disorders. Genet Epidemiol 7:3-16, 1990.
16. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and pathophysiological implications. Lancet 361:417-419, 2003.
17. Ban TA. Neuropscyhopharmacology and the genetics of schizophrenia-a history of the diagnosis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:753-762, 2004.
18. Barettini W. Evidence of shared susceptibility in bipolar disorder and schizophrenia. Am J Med Genet 123C:59-64, 2003.
19. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altschuler L, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 160:1263-1271, 2003.
20. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669, 1987.
21. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25:409-432, 2002.
22. Mueser KT, McGurk SR. Schizophrenia. Lancet 363:2063-2072, 2004.
23. Amminger GP, Pape S, Rock D, Roberts SA, Ott SL, Squires-Wheeler E, Kestenbaum C, Erlenmeyer-Kimling L. Relationship between childhood behavioral disturbance and later schizophrenia in the New York High-Risk Project. Am J Psychiatry 156:525-530, 1999.
24. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Cognitive and behavioral markers for schizophrenia in apparently healthy adolescents. Am J Psychiatry 156:1328-1335, 1999.
25. Walker E, Lewine RJ. Prediction of adult-onset schizophrenia from childhood home movies of the patients. Am J Psychiatry 147:1052-1056, 1990.
26. DeLisi LE, Hoff AL, Schwartz JE, Schields GW, Halthore SN, Gupta SM, Henn FA, Anand AK. Brain morphology in first-episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study. Biol Psychiatry 29:159-175, 1991.
27. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 155:1711-1717, 1998.
28. Lieberman JA, Bogerts B, Degreef G, Ashtari M, Lantos G, Alvir J. Qualitative assessment of brain morphology in acute and chronic schizophrenia. Am J Psychiatry 149:784, 1992.
29. Lieberman JA, Jody D, Alvir JM, Ashtari M, Levy DL, Bogerts B, Degreef G, Mayerhoff I, Cooper T. Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia. Prevalence and clinical correlates. Arch Gen Psychiatry 50:357-368, 1993.
30. Lim KO, Tew W, Kushner M, Chow K, Matsumoto B, DeLisi LE. Cortical gray matter volume deficit in patients with first-episode schizophrenia. Am J Psychiatry 153:1548-1553, 1996.
31. Nopoulos P, Torres I, Flaum M. Brain morphology in first episode schizophrenia. Am J Psychiatry 152:1721-1723, 1995.
32. Zipursky R, Lambe EK, Kapur S, Mikulis DJ. Cerebral gray matter volume deficits in first episode psychosis. Arch Gen Psychiatry 55:540-546, 1998.
33. Akbarian S, Kim JJ, Potkin SG, Hetrick WP, Bunney WEJ, Jones EG. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch Gen Psychiatry 53:425-436, 1996.
34. Lewis DA. Development of the prefrontal cortex during adolescence: insights into vulverable neural circuits in schizohrenia. Neuropychopharmacology 16:385-398, 1997.
35. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex. Arch Gen Psychiatry 52:805-818, 1995.
36. Rajkowska G, Harlaris A, Selemon LD. Reductions in neuronal and glia density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 49:741-752, 2001.
37. Black JE, Kodish IA, Grossman AW, Klintsova AY, Orlovskaya D, Vostrikov V, Uranova N, Greenough WT. Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. Am J Psychiatry 161:742-744, 2004.
38. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 57:65-73, 2000.
39. Lewis DA, Volk DW, Hashimoto T. Selective alterations in prefrontal cortical GABA transmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology 2004:143-150, 2004.
40. Weinberger DR, Berman KF. Prefrontal function in schizophrenia: confounds and controversies. Phil Trans Royal Soc London Series B: Biol Sci 351:1495-1503, 1996.
41. Clinton SM, Meador-Woodruff JH. Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophrenia Res 69:237-253, 2004.
42. Andreasen NC, Arndt S, Swayze IIV, Cizadlo T, Flaum M, O'Leary D, Ehrhardt JC, Yuh WTC. Thalamic abnormalities in schizophrenia visualized through magnetic resonance averaging. Science 266:294-298, 1994.
43. Strakowski SM, DelBello MP, Sax KW, Zimmerman ME, Shear PK, Hawkins JM, Larson ER. Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. Arch Gen Psychiatry 56:254-260, 1999.
44. Wright IC, Rabe-Hesketh S, Woodruff PWR, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 157:16-25, 2000.
45. Altshuler LL, Bartzokis G, Grieder T, Curran J, Mintz J. Amygdala enlargement in bipolar disorder and hippocampal reduction in schizophrenia: an MRI study demonstrating neuroanatomic specificity. Arch Gen Psychiatry 55:663-664, 1998.
46. Harrison PJ. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology 174:151-162, 2004.
47. Dalman C, Allebeck P, Cullberg J, Grunewald C, Koster M. Obstetric complications and the risk of schizophrenia: a longitudinal study of a national birth cohort. Arch Gen Psychiatry 56:234-240, 1999.
48. McCarley RW, Wible CG, Frumin M, Hirayasu Y, Levitt J, Fischer IA, Shenton ME. MRI anatomy of schizophrenia. Biol Psychiatry 45:1099-1119, 1999.
49. Chakos MH, Lieberman JA, Alvir J, Bilder RM, Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 345:456-457, 1995.
50. Lang DJ, Kopala LC, Vandorpe RA, Rui Q, Smith GN, Goghari VM, Lapointe JS, Honer HG. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Am J Psychiatry 161:1829-1836, 2004.
51. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyke CH, Charney DS, Innis RB, Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767, 1998.
52. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 997:8104-8109, 2000.
53. Laruelle M, Abi-Dargham A, Gil R, Kegeles LS, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phase. Biol Psychiatry 46:56-72, 1999.
54. Laruelle M, Abi-Dargham A, van Dyke CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Finado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235-9240, 1996.
55. Deicken RF, Feiwell R, Schuff N, Soher B. Evidence for altered vermis neuronal integrity in schizophrenia. Psychiatry Res 107:125-134, 2001.
56. Ende G, Hubrich P, Walter S, Weber-Fahr W, Kammerer N, Brauss DF, Henn FA. Further evidence for altered cerebellar neuronal integrity in schizophrenia. Am J Psychiatry 162:790-792, 2005.
57. Levitt JJ, McCarley RW. Nestor PG, Petrescu C, Donnino R, Hirayasu Y, Kikinis R, Jolesz FA, Shenton ME. Quantitative volumetric MRI study of the cerebellum and vermis in schizophrenia: clinical and cognitive correlates. Am J Psychiatry 156:1105-1107, 1999.
58. Badner JA, Gershon ES. Metaanalysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 7:405-411, 2002.
59. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, Williams NM, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder. Part II: schizophrenia. Am J Hum Genet 73:34-48, 2003.
60. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 7:877-892, 2002.
61. Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E, et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 72:83-87, 2003.
62. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 71:337-348, 2002.
63. Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M, Albus M, et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 72:185-190, 2003.
64. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 99:13675-13680, 2002.
65. Chowdari KV, Mirnics K, Semwal P, Wood J, Lawrence E, Bhatia T, et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 11:1373-1380, 2002.
66. Mimics K, Middleton FA, Lewis DA, Levitt P. Delineating novel signature patterns of altered gene expression in schizophrenia using gene microarrays. Sci World J 1:114-116, 2001.
67. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, Weizman A, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 71:1296-1302, 2002.
68. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98:6917-6922, 2001.
69. Liu H, Heath SC, Sobin C, Roos JL, Galke BL, Blundell ML, et al. Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci USA 99:3717-3722, 2002.
70. Gershon ES, Badner JA. Incorporation of molecular data and redefinition of phenotype: new approaches to genetic epidemiology of bipolar manic depressive illness and schizophrenia. Dialogues Clin Neurosci 3:63-71, 2001.
71. Weinberger DR. Biological phenotypes and genetic research in schizophrenia. World Psychiatry 1:2-6, 2002.
72. Holzman PS. Behavioral markers of schizophrenia useful for genetic studies. Psychiatry Res 26:427-445, 1992.
73. Levy DL, Holzman PS, Matthysse S, Mendell NR. Eye tracking and schizophrenia: a selective review. Schizophr Bull 20:47-62, 1994.
74. McDowell JE, Brenner CA, Myles-Worsley M, Coon H, Byerley W, Clements B. Ocular motor delayed-response task performance among patients with schizophrenia and their biological relatives. Psychophysiology 38:153-156, 2001.
75. Adler LE, Oliney A, Waldo M, Harris JG, Griffith J, Stevens K, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24:189-202, 1998.
76. Freedman R, Adler LE, Leonard S. Alternative phenotypes for the complex genetics of schizophrenia. Biol Psychiatry 45:551-558, 1999.
77. Freedman D, Squires-Wheeler E. Event-related potentials (ERP) as an indicator for schizophrenia. Schizophr Bull 20:63-74, 1994.
78. Tsuang MT, Stone WS, Faraone SV. Understanding predisposition to schizophrenia: toward intervention and prevention Can J Psychiatry 47:518-526, 2002.
79. Arolt V, Lencer R, Nolte A, Muller-Myhsok B, Purman S, Schurman M, et al. Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurrence of the disease Am J Med Genet 67:564-569, 1996
80. Freedman R, Coon H, Myles-Worsley M, Orr-Urtrager A, Olincy A, Davis A, et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 94:587-592, 1997.
81. Leonard S, Gault J, Moore T, Hopkins J, Robinson M, Olincy A, et al. Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH Genetics Initiative. Am J Med Genet 81:308-312, 1998.
82. Faraone SV, Seidman LJ, Kremen WS, Toomey R, Pepple JR. Tsuang MT. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a 4-year follow-up study. J Abnorm Psychology 108:176-181, 1999.
83. Hariri AR, Weinberger DR. Imaging genomics. Br Med Bull 65:259-270, 2003.
84. Delay J, Deniker P, Harl JM [Therapeutic use in psychiatry of phenothiazine of central elective action]. Ann Med Psychol 110:112-117, 1952.
85. Carlsson A, Lindquist M. Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20:140-144, 1963.
86. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483, 1976.
87. Seeman P, Lee T, Chau-Wong M. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719, 1976.
88. Lehmann HE, Ban TA. The history of psychopharmacology of schizophrenia. Can J Psychiatry 42:152-162, 1997.
89. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-296, 1988.
90. Meltzer HY, Alphs L, Green AI, Altamura C, Anand R, Bertoldi AB, Chouinard G, Islam Z, Kane J, Krishnan R, Lindenmayer J-P, Potkin S; International Suicide Prevention Trial Group. Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry 60:82-91, 2003.
91. Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuro-Psychopharmacol Biol Psychiatry 28:1213-1219, 2004.
92. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 10:317-336, 2004.
93. Bolonna AA, Kerwin RW. Partial agonism and schizophrenia. Br J Psychiatry 186:7-10, 2005.
94. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson CA, Tamminga CA. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl) -N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiatry 43:2-11, 1998.
95. Coyle JT, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms, Psychopharmacology 174:32-38, 2004.
96. Millan MJ. N-methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 179:30-53, 2005.
97. Coyle JT, Tsai G, Goff DC. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Target CNS Neurol Disord 1:183-189, 2002.
98. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72:225-234, 2005.
99. Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res 71:239-248, 2004.
100. Carpenter WT, Buchanan RW, Javitt DC, Marder SR, Schooler NR, Heresco-Levy U, Gold JM. Is glutamatergic therapy efficacious in schizophrenia. Neuropsychopharmacology 29 [Suppl 1]:S110, 2004.
101. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277:968-981, 1996.
102. Marder SR. Limitations of dopamine-D2 antagonists and the search for novel antipsychotic strategies. Neuropsychopharmacology 21 [Suppl 6]:S117, 1999.
103. 2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology 17:175-185, 1997.
104. Meltzer HY, Arvanitis L, Bauer D, Rein W; Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorders. Am J Psychiatry 161:975-984, 2004.
105. Kramer MS, Last B, Getson A, Reines SA; D4 Dopamine Antagonist Group. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 54:567-572, 1997.
106. Corrigan MH, Gallen CC, Bonura L, Mechant KM; Sonepiprazole Study Group. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. Biol Psychiatry 55:419-445, 2004.
107. Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Riviere M-E, Papillon-Downey C. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am J Psychiatry 156:419-425, 1999.
108. Isaac M, Isaac M, Holloway F. Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care. Hum Psychopharmacol 20:207-210, 2005.
109. Lipska BK. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci 29:282-286, 2004.
110. Beauregard M, Bachevalier J. Neonatal insult to the hippocampal region and schizophrenia: a review and a putative animal model. Can J Psychiatry 41:446-456, 1996.
111. Lipska BK, Jaskiw GE, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 9:67-75, 1993.
112. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47:181-188, 1990.
113. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56:301-307, 2004.
114. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 68:283-297, 2004.
115. Pongrac J, Middleton FA, Lewis DA, Levitt P, Mimics K. Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders. Neurochem Res 27:1049-1063, 2002.
116. Palfreyman MG, Hook DJ, Klimczak LJ, Brockman JA, Evans DM, Altar CA. Novel directions in antipsychotic target identification using gene arrays. Curr Drug Targets-CNS Neurol Disord 1:227-238, 2002.
117. Kerri S, Janka Z. Critical evaluation of cognitive dysfunctions as endophenotypes of schizophrenia. Acta Psychiatr Scand 110:83-91, 2004.
118. Bertolino A, Caforio G, Blasi G, De candia M, Latorre V, Petruzzella V, Altamura M, Nappi G, Papa S, Callicott JH, Mattay VS, Bellomo A, Scarabino T, Weinberger DR, Nardini M. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 161:1798-1805, 2004.